Olympus Secures CMS Reimbursement Rates for New ESD Procedure Codes
Olympus Corporation announced final CMS valuations for new ESD CPT codes, advancing U.S. patient access to organ-sparing GI endoscopy procedures in 2027.
Olympus Corporation has announced the publication of final Centers for Medicare & Medicaid Services valuations and calendar year 2027 reimbursement rates tied to newly established CPT codes for endoscopic submucosal dissection, a minimally invasive gastrointestinal procedure designed to remove tumors while preserving the affected organ.
The Tokyo- and Center Valley, Pennsylvania-based medical technology company said the finalized rates represent a significant step toward broadening patient access to ESD in the United States, where the procedure has historically faced reimbursement barriers that limited its adoption compared with markets in Asia and Europe.
Read more Huawei Showcases AI Scalability Tools for Finance at Singapore FinTech Fest →
ESD is considered an organ-sparing alternative to surgery for certain early-stage gastrointestinal cancers and precancerous lesions. By allowing clinicians to remove larger or more complex lesions through an endoscope rather than open or laparoscopic surgery, the technique can reduce patient recovery time and the risk of complications associated with more invasive interventions.
The establishment of dedicated CPT codes with defined CMS valuations is widely regarded in the medical device sector as a prerequisite for mainstream procedural uptake in the U.S. healthcare system, since clear reimbursement pathways reduce financial uncertainty for hospitals and outpatient facilities considering investment in the technique and related equipment.
Olympus, which markets endoscopy systems used in ESD procedures, positioned the development as consistent with its broader strategic focus on endoscopy-enabled care. The rates are set to take effect under the CY2027 Medicare Physician Fee Schedule. Continue reading at All Financial Services & Investing.